Acute myeloid leukaemia (AML) is a fast-growing blood cancer that often becomes resistant to standard treatments. This resistance is linked to proteins that prevent cancer cells from dying. A new class of drugs, called BH3 mimetics, is showing promise by targeting these proteins and helping treatments work more effectively. One such drug, venetoclax, has already improved outcomes for older patients or those unable to undergo intensive chemotherapy. When combined with existing therapies, it has led to better response rates and longer survival, earning approval from the U.S. FDA.

In this review, co-led by Dr Alan Prem Kumar, the transformative potential of BH3 mimetics in AML therapy is explored, including ongoing research into new drug combinations and strategies aimed at refining treatment approaches. The ultimate goal is to improve outcomes for patients by making therapies more effective and better tailored to individual needs.

Click here to read more